soloMER-Drug-Conjugates (SDCs)

The qualities of the soloMER domains (small, stable, flexible etc) make them ideal for the delivery and tumour penetration of toxic war-heads deep into solid tumours.

Through collaboration and partnerships we are already delivering our first oncology late-pre-clinical stage candidate molecules (target ROR1).  Using flexible formatting approaches we can develop, bi and tri specificities, tailor half-life with our NDure™ domain and potent systemic therapeutics with data now presented at a number high-profile meetings in 2019 and 2020.


Using a related conjugation strategy, we have generated drug-loaded, anti-angiogenesis nanoparticles for the treatment of pancreatic cancer.

Queen’s University Belfast


The flexibility of soloMER building blocks facilitates the generation of bi-specific and bi-paratopic formats.  These characteristics have been exploited to deliver a number of earlier stage assets in immuno-oncologyWe are keen to discuss the fast-track development (through partnership) of these potent IO molecules.

See publications section of our website for the data that supports these programs